The phrase "Value Based Cancer Care" is typically used to mean the entire oncology team is participating in the consideration of the cost-value issues specific to cancer treatments. Dr. Yu, the leader of the American Society for Clinical Oncology (ASCO) recently said in the ASCO Annual Report, "It is critical that patients and physicians understand the value of treatment options. In any treatment situation, the health and individual needs of the patient are paramount, and determining the value of any particular cancer treatment is a highly personalized process that must be determined between a physician and patient." How do you communicate value to patients at the time of a cancer diagnosis? Dollars? Life expectancy? Quality of life? Effort of customization? Personalized treatment based on genomic factors?
The 2015 annual report on “Clinical Cancer Advances” from ASCO also reported that faster and less expensive genomic testing (eg, next-generation sequencing) “is poised to revolutionize personalized medicine, both as a diagnostic tool and a way to tailor targeted treatments to individual patients.” We might just see genomic testing on all tumors in the near future, rather than far-off future.
Perhaps, value-based care will likely have 2 components - the internal value monitoring and the external communication of the value proposition to the patient. It all remains to be seen.